TEVA PHARMACEUTICAL INDUSTRIES LTD business relationships
Companies named in TEVA PHARMACEUTICAL INDUSTRIES LTD’s 10-K filed 2026-02-03, and public companies whose annual reports name TEVA PHARMACEUTICAL INDUSTRIES LTD. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.7 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Layers: PeptidesGLP-1 & obesity
Named in TEVA PHARMACEUTICAL INDUSTRIES LTD’s annual report 8
“On December 19, 2025, Alvotech and Teva announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc., concerning the launch of Alvotech's proposed biosimilar to Eylea” SEC filing
“In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. ("Takeda"), for the research, development, manufacture and commercialization of ATTENUKINE” SEC filing
“In collaboration with Sanofi.” SEC filing
“Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceutical industry ("IQVIA"), unless otherwise stated.” SEC filing
“On December 19, 2025, Alvotech and Teva announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc., concerning the launch of Alvotech's proposed biosimilar to Eylea” SEC filing
“...sed biosimilar to Prolia ® (denosumab) and to Xgeva ® (denosumab) were submitted for regulatory review in the U.S. Our proposed biosimilars to Simponi ® , Simponi Aria ® (golimumab), and Eylea ® (aflibercept), which are in collaboration with Alvotech, were submitted for regulatory review in the U.S.” SEC filing
“On November 26, 2023, Teva entered into a license agreement with Biolojic Design Ltd. ("Biolojic"), pursuant to which Teva received exclusive rights to develop, manufacture and globally commercialize a BD9 multibody with potential indications including atopic dermatitis and asthma.” SEC filing
“Under the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, the global investment firm, will have the lead role in the operational execution and management of the planned clinical trials.” SEC filing
Companies whose annual reports name TEVA PHARMACEUTICAL INDUSTRIES LTD 6
“During the fiscal year ended March 31, 2025, Takeda decided to enter into discussions with Teva Pharmaceutical Industries Ltd. to dissolve a joint venture business in Japan primarily focused on generic medicines and long-listed products.” SEC filing
“In December 2020, Teva Pharmaceutical Industries Ltd ("TEVA") has agreed to revise a settlement agreement from March 2019, which was comprised of past agreement for collaboration in the development, manufacturing and commercialization of solutions for the burn and chronic wound care markets, as well...” SEC filing
“...October 17, 2017, we entered into a Settlement Agreement and a Licensing Agreement with Actavis (which is now owned by Teva Pharmaceutical Industries Limited), pursuant to which we granted Actavis the right to manufacture and market its now approved generic version of Adzenys under the ANDA beginni...” SEC filing
“Exclusive License and Distribution Agreement with Teva Pharmaceutical Industries Ltd.” SEC filing
“...entered into a term sheet with Assia Chemical Industries Ltd. (Assia), doing business as TAPI Technology & API Series (TAPI), a subsidiary of Teva Pharmaceutical Industries Ltd. and in December 2025, the Company entered into a license agreement with TAPI replacing the term sheet (License Agreement).” SEC filing
“| On February 4, 2025, we announced the award of a new contract with Teva Pharmaceutical Industries Ltd. (Teva), to install the SaverOne System across its entire fleet of 50 pharmaceutical delivery trucks.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.